RE: Massive news!!!20 Jan 2019 19:16
So early Q1 fda approval and this think any US shorts are going to have to close soon.
In addition to the above priority programs, Midatech's gold nanoparticle technology MidaCore continues to be evaluated via several research collaborations, including clinically as a drug or peptide delivery platform for autoimmune disease as a vaccine for diabetes with the Phase I study due to read out early 2019, as well as preclinically for solid tumour cancer vaccines and treatments, viral vaccines, and psoriasis treatment.